$17.360
-0.391 (-2.25%)At close
EMPG News
EMPG Events
Nasdaq Notifies Empro of Delisting
Nasdaq announced that it has notified Empro that its securities will be delisted from Nasdaq on July 27 unless the company appeals to a listing qualifications hearings panel. The securities will remain halted, and unavailable to trade, until any appeal is resolved. Following removal from Nasdaq the securities may be eligible for trading in the over-the-counter market.
Nasdaq Suspends Trading of Empro
The Nasdaq Stock Market (NDAQ) announced that trading is halted in Empro Group (EMPG) for additional information requested from the company. Previously, the SEC effected a trading suspension in EMPG from 04:00:00 on October 9, 2025 to 23:59:00 on October 22, 2025. The last sale price of the company's ordinary shares was $17.36. Trading will remain halted until Empro Group has fully satisfied Nasdaq's request for additional information.
Empro confirms listing on Nasdaq Capital Market
Empro Group confirmed its listing on the Nasdaq Capital Market under the ticker symbol "EMPG" and the completion of its previously announced initial public offering of ordinary shares. Empro's ordinary shares commenced trading on July 2, 2025, marking a historic milestone as the first beauty brand from Malaysia to be publicly listed in the United States. The IPO was upsized from $5.0 million to $5.5 million, with 1,375,000 ordinary shares priced at $4.00 per share. The underwriter for the IPO exercised its over-allotment option in full as a result of partial exercises on each of July 29, 2025 and July 31, 2025, purchasing an aggregate of 206,250 additional ordinary shares at the $4.00 public offering price. In total, the IPO generated gross proceeds of approximately $6.325 million, before deducting underwriting discounts and offering expenses. The offering was conducted on a firm commitment basis, with R.F. Lafferty & Co., Inc. serving as the sole underwriter. ARC Group acted as the sole financial advisor to the Company.
Empro closes remaining portion of underwriter's over-allotment option
Empro closed the sales of an additional 91,250 ordinary shares of the Company, representing the exercise of the remaining portion of the underwriter's over-allotment option granted in connection with the Company's initial public offering, at the IPO price of $4.00 per share, less underwriting discounts. As a result, the Company has raised gross proceeds of $365,000 in addition to the previously announced IPO gross proceeds of approximately $5,500,000 and the previously announced gross proceeds of $460,000 arising from the partial exercise by the underwriter of its over-allotment option that closed on July 30, 2025, for aggregate gross of proceeds of $6,325,000, before deducting underwriting discounts and other offering expenses. The Offering was conducted on a firm commitment basis. R.F. Lafferty & Co. acted as the sole underwriter for the Offering. Pryor Cashman acted as U.S. counsel to the Company, and Sichenzia Ross Ference Carmel acted as U.S. counsel to the Underwriter in connection with the Offering.
Empro closes underwriter's partial exercise of over-allotment option
Empro Group closed the sales of an additional 115,000 ordinary shares of the Company, representing the partial exercise of the underwriter's over-allotment option granted in connection with the Company's initial public offering at the IPO price of $4.00 per share, less underwriting discounts. As a result, the Company has raised gross proceeds of $460,000 in addition to the previously announced IPO gross proceeds of approximately $5,500,000, before deducting underwriting discounts and other offering expenses. The Offering was conducted on a firm commitment basis. R.F. Lafferty & Co., Inc. acted as the sole underwriter for the Offering. Pryor Cashman LLP acted as U.S. counsel to the Company, and Sichenzia Ross Ference Carmel LLP acted as U.S. counsel to the Underwriter in connection with the Offering.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.